Mukul Agarwal

Corporate Officer/Principal at FORTY SEVEN, INC.

Consumer Services

Health Technology

Profile

Mukul Agarwal is currently the Vice President of Corporate Development at Forty Seven, Inc. Prior to this, he worked as the Senior Director of Corporate Development and Strategy at Anacor Pharmaceuticals LLC.
From 2016 to 2019, he was the Vice President of Business Development at Revance Therapeutics, Inc. Mr. Agarwal holds a Master's in Business Administration from Carnegie Mellon University, a graduate degree from The Ohio State University, and an undergraduate degree from the Indian Institute of Technology New Delhi.

Mukul Agarwal active positions

Companies	Position	Start
FORTY SEVEN, INC.	Corporate Officer/Principal	-

All active positions of Mukul Agarwal

Former positions of Mukul Agarwal

Companies	Position	End
REVANCE THERAPEUTICS, INC.	Corporate Officer/Principal	2019-02-28
ANACOR PHARMACEUTICALS INC	Corporate Officer/Principal	-

See the detail of Mukul Agarwal's experience

Training of Mukul Agarwal

Carnegie Mellon University	Masters Business Admin
The Ohio State University	Graduate Degree
Indian Institute of Technology New Delhi	Undergraduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Mukul Agarwal's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
REVANCE THERAPEUTICS, INC.	Health Technology

Private companies	2
Anacor Pharmaceuticals LLC Anacor Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Anacor Pharmaceuticals, Inc. develops medical solutions. The firm operates as a biopharmaceutical company, which focuses on discovering, developing, and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. The company was founded by Lucy Shapiro, Stephen J. Benkovic, and David P. Perry in 2000 and is headquartered in Palo Alto, CA.	Health Technology
Forty Seven, Inc. Forty Seven, Inc. Pharmaceuticals: MajorHealth Technology Forty Seven, Inc. develops therapies that target cancer immune evasion pathways. It develops Hu5F9-G4, a monoclonal antibody against human CD47 that potentially has applications spanning multiple tumor types and treatment modalities. The company was founded by Irving L. Weissman, Ravi Majeti, Mark Chao and Jens-Peter Volkmer in 2014 and is headquartered in Menlo Park, CA.	Health Technology

Private companies